DIAMOND

What this means for you

This application is over — abandoned 15 Mar 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number

97220299

Mark type

Stylized text

Filed

14 Jan 2022

Abandoned

15 Mar 2023

Attorney of record

Christina M. Licursi

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of neurological diseases and disorders, central nervous system diseases and disorders, neurodegenerative diseases and disorders, immune system-related diseases and disorders, and metabolic diseases and disorders
• Class 042 — Scientific and technological services: Software for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and transmission of data, images, information and artificial intelligence in the fields of drug discovery and healthcare, biomedical and genomic research; software featuring machine learning and artificial intelligence for data analysis in the fields of drug discovery and healthcare, biomedical and genomic research; software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks; software for genetic assessment and identification of cancer, diseases, health status and metrics, and gene mutations for scientific, medical, diagnostic, treatment, and research purposes; software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; software for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement; scientific research, namely, research and analysis services featuring artificial intelligence and machine learning analytics in the fields of healthcare, biomedical and genomic research; research and development in the field of drug discovery and development, computational biology, bioinformatics, and genomics; research and development of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of neurological diseases and disorders, central nervous system diseases and disorders, neurodegenerative diseases and disorders, immune system-related diseases and disorders, and metabolic diseases and disorders; technical scientific consultation and product development for others in the fields of drug discovery and development, pharmaceuticals, biotechnology and immunology; consulting in the fields of drug discovery and development, clinical trial management and patient engagement in drug clinical trials

Owner

• Vesalius Therapeutics Inc., Cambridge, MA, US

Prosecution history

• 03 Apr 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
• 01 Apr 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
• 01 Apr 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
• 14 Sept 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 14 Sept 2022 — NON-FINAL ACTION E-MAILED
• 14 Sept 2022 — NON-FINAL ACTION WRITTEN
• 18 Aug 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 17 Aug 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 17 Aug 2022 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 08 Jul 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 08 Jul 2022 — NON-FINAL ACTION E-MAILED
• 08 Jul 2022 — NON-FINAL ACTION WRITTEN
• 05 Jul 2022 — ASSIGNED TO EXAMINER
• 21 Jan 2022 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED